Skip to main content
. 2022 Jul 15;65(14):9662–9677. doi: 10.1021/acs.jmedchem.2c00704

Figure 1.

Figure 1

Selected FDA-approved first-, second-, and third-generation EGFR tyrosine kinase inhibitors.